18 November 2024
Kromek Group
plc
("Kromek"
or the "Group")
Notice of
AGM and Publication of Annual Report
Kromek (AIM: KMK), a leading developer of radiation
and bio-detection technology solutions for the advanced imaging and
CBRN detection segments, gives notice that its Annual General
Meeting ("AGM") will be held at 9:30am on Friday 13 December 2024
in the Kromek 'Biosecurity' Boardroom at Explorer 1
Building, North East Technology Park (NETPark), Thomas Wright Way,
Sedgefield, County Durham, TS21 3FF.
The notice of AGM and form of proxy,
along with the Group's annual report and accounts for the year
ended 30 April 2024, have today been posted to those shareholders
who have requested paper communications. These documents are also
available on the Investor Relations section of the Group's website
at https://www.kromek.com/investor-relations/
and can be accessed by clicking on the "AGM 2024" page.
For further
information, please contact:
Kromek Group
plc
|
|
Arnab Basu, CEO
Paul Farquhar,
CFO
|
+44 (0)1740 626 060
|
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
|
|
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate
Finance
Tim Redfern - ECM
Michael Johnson/Tamar Cranford-Smith - Sales
|
+44 (0)20
7220 0500
|
Gracechurch Group
(Financial PR)
|
|
Harry Chathli/Claire Norbury/Henry
Gamble
|
+44 (0)20 4582 3500
|
Kromek Group
plc
Kromek Group plc is a leading developer of radiation
detection and bio-detection technology solutions for the advanced
imaging and CBRN detection segments. Headquartered in County
Durham, UK, Kromek has manufacturing operations in the UK and US,
delivering on the vision of enhancing the quality of life through
innovative detection technology
solutions.
The advanced imaging segment comprises the medical
(including CT and SPECT), security and industrial markets. Kromek
provides its OEM customers with detector components, based on its
core cadmium zinc telluride (CZT) platform, to enable better
detection of diseases such as cancer and Alzheimer's, contamination
in industrial manufacture and explosives in aviation
settings.
In CBRN detection, the Group provides nuclear
radiation detection solutions to the global homeland defence and
security market. Kromek's compact, handheld, high-performance
radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect
critical infrastructure, events, personnel and urban environments
from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions
in the CBRN detection segment. These consist of fully automated and
autonomous systems to detect a wide range of airborne
pathogens.
Kromek is listed on AIM, a market of the London Stock
Exchange, under the trading symbol
'KMK'.